ReviewCurrent hematologic malignancy reports2012
Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas.
Review in Current hematologic malignancy reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma.Blood advances · 2024Article
- Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.International journal of molecular sciences · 2024Review
- Article
- Review
- Interplay between innate immunity and the viral oncoproteins Tax and HBZ in the pathogenesis and therapeutic response of HTLV-1 associated adult T cell leukemia.Frontiers in immunology · 2022Review
- Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies.Frontiers in oncology · 2022Review
- Chimeric antigen receptor T-cell therapy for T-ALL and AML.Frontiers in oncology · 2022Review
- Adult T-Cell Leukemia: a Comprehensive Overview on Current and Promising Treatment Modalities.Current oncology reports · 2021Review
- CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?Stem cell research & therapy · 2021Review
- Novel Treatments of Adult T Cell Leukemia Lymphoma.Frontiers in microbiology · 2020Review
- T-cell positioning by chemokines in autoimmune skin diseases.Immunological reviews · 2019Review
- CCL17/TARC and CCR4 expression in Merkel cell carcinoma.Oncotarget · 2018Article
- Human T-cell lymphotropic virus type 1 and its oncogenesis.Acta pharmacologica Sinica · 2017Review
- Detection of Tax-specific CTLs in lymph nodes of adult T-cell leukemia/lymphoma patients and its association with Foxp3 positivity of regulatory T-cell function.Oncology letters · 2017Article
- Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.Frontiers in immunology · 2017Review
- Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders.Journal for immunotherapy of cancer · 2016Review
- Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges.Frontiers in immunology · 2015Review
- The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas.Blood cancer journal · 2014Article
- Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan.Journal of clinical pharmacy and therapeutics · 2014Article
- The role of chemoattractant receptors in shaping the tumor microenvironment.BioMed research international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral T-cell lymphoma (PTCL) is a group of lymphoid malignancy that remains difficult to treat, as most PTCL becomes refractory or relapses, and thus there is an unmet medical need for novel treatment modalities. CC chemokine receptor 4 (CCR4) is expressed in various types of PTCL including adult T-cell leukemia-lymphoma (ATL), which has the worst prognosis among them. A phase II study of a defucosylated, humanized anti-CCR4 monoclonal antibody, mogamulizumab (KW-0761), yielded an overall response rate of 50 % (13/26) and a median progression-free survival of 5.2 months in relapsed patients with CCR4-positive ATL who had been previously treated with chemotherapy. Mogamulizumab also showed potential efficacy for cutaneous T-cell lymphoma in a US phase I/II study. Further preclinical and clinical investigations are needed to examine whether concomitant use of this novel agent with other agents with different mechanisms of action would be more effective for ATL and other PTCLs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.